Imaging of PARP Upregulation in Small Cell Neuroendocrine Lung Carcinoma with [123I] I-PARPi SPECT/CT

Introduction: PARP (poly[ADP-ribose] polymerase) inhibitors (PARPi) are effective oncology agents for tumors harboring certain genetic mutations that make them resistant to conventional therapies such as chemotherapy and radiotherapy. We demonstrate, for the first time, that iodine-123 radiolabeled PARPi SPECT/CT imaging can be used as a marker of PARP upregulation and a predictor of chemotherapy resistance in a patient with small cell neuroendocrine tumor.